Skip to main content

David Morris Marks, MD

Adjunct Associate Professor in the Department of Psychiatry and Behavioral Sciences
Associate Professor in Community and Family Medicine
Division: 
Adult Psychiatry & Psychology
Category: 
Office: 932 Morreene Road, Durham, NC 27705
Campus Mail: DUMC Box 3333 Med Ctr, DUMC, Durham, NC 27710

Education and Training

  • M.D., University of Texas, Medical Branch at Galveston, 1995

Publications

Lin, Katherine A., Kingshuk Roy Choudhury, Bharath G. Rathakrishnan, David M. Marks, Jeffrey R. Petrella, P Murali Doraiswamy, and P Murali Alzheimer’s Disease Neuroimaging Initiative. “Marked gender differences in progression of mild cognitive impairment over 8 years.” Alzheimers Dement (N Y) 1, no. 2 (September 1, 2015): 103–10. https://doi.org/10.1016/j.trci.2015.07.001.

Full Text

Marks, David M., and Amy Newhouse. “Durability of Benefit From Repeated Intravenous Lidocaine Infusions in Fibromyalgia Patients: A Case Series and Literature Review.” Prim Care Companion Cns Disord 17, no. 5 (2015). https://doi.org/10.4088/PCC.15br01804.

Full Text

Marks, David M., Chi-Un Pae, and Ashwin A. Patkar. “A double-blind, placebo-controlled, parallel-group pilot study of milnacipran for chronic radicular pain (sciatica) associated with lumbosacral disc disease.” Prim Care Companion Cns Disord 16, no. 4 (2014). https://doi.org/10.4088/PCC.14m01658.

Full Text

Kim, Jeong Lan, Shilpa Rele, David M. Marks, Prakash S. Masand, Pallavi Yerramsetty, Robert A. Millet, Richard S. Keefe, and Ashwin A. Patkar. “Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial.” Prim Care Companion Cns Disord 15, no. 6 (2013). https://doi.org/10.4088/PCC.13m01555.

Full Text

Marks, David M., and Michael P. Bolognesi. “Open-label milnacipran for patients with persistent knee pain 1 year or longer after total knee arthroplasty: a pilot study.” Prim Care Companion Cns Disord 15, no. 4 (2013). https://doi.org/10.4088/PCC.12m01496.

Full Text

Marks, David M., Jonathan S. Abramowitz, and Glen I. Spielmans. “Concerns about data reporting and interpretation in "Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial".” J Psychiatr Res 46, no. 5 (May 2012): 692–93. https://doi.org/10.1016/j.jpsychires.2012.02.002.

Full Text

Marks, D. M. “Amitifadine hydrochloride: Triple reuptake inhibitor treatment of depression.” Drugs of the Future 37, no. 4 (April 1, 2012): 241–46. https://doi.org/10.1358/dof.2012.37.4.1782933.

Full Text

Marks, D. M. “Amitifadine hydrochloride: Triple reuptake inhibitor treatment of depression.” Drugs of the Future 37, no. 4 (January 1, 2012): 241–46. https://doi.org/10.1358/dof.2012.037.04.1782933.

Full Text

Hardy, T. A., R. R. Henry, T. D. Forrester, L. A. Kryzhanovskaya, G. M. Campbell, D. M. Marks, and S. Mudaliar. “Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.” Diabetes Obes Metab 13, no. 8 (August 2011): 726–35. https://doi.org/10.1111/j.1463-1326.2011.01398.x.

Full Text

Pae, Chi-Un, Haresh Tharwani, David M. Marks, Prakash S. Masand, and Ashwin A. Patkar. “Atypical depression: a comprehensive review.” Cns Drugs 23, no. 12 (December 2009): 1023–37. https://doi.org/10.2165/11310990-000000000-00000.

Full Text

Pages